Biopharmaceutical company Xeris Biopharma entered into an amended and restated senior secured term loan agreement with funds managed by Hayfin Capital Management. The agreement provides Xeris $200 million of capital at close and the ability to draw down another $15.2 million to redeem its outstanding 5% convertible senior notes due 2025.